The forecasted import of insulin to China shows a steady upward progression from 4.14 thousand kilograms in 2024 to 4.85 thousand kilograms in 2028. The year-on-year growth rates are indicative of consistent demand, with an increase from 4.14 in 2024 to 4.32 in 2025, translating to a 4.35% rise. Similarly, from 2025 to 2026, the value increases by 4.17%, followed by a 3.78% rise in 2027 and a 3.86% growth in 2028. Comparing to 2023, where imported insulin stood at 4.00 thousand kilograms, the 2024 forecast shows a 3.5% increase, and the Compound Annual Growth Rate (CAGR) over the five years is approximated at around 4%.
Future trends to watch include potential changes in healthcare policies, domestic insulin production capabilities, and advancements in diabetes management technologies, which could influence import volumes. Monitoring economic factors and population health trends will also be crucial in anticipating future demand.
